NCT02127307View on ClinicalTrials.gov

Phase 4 Study to Demonstrate Prognostic Usefulness of AdreView™ Scintigraphy for Identifying Subjects With Heart Failure Who Will Experience Death During 60 Months Follow-up.

CompletedOBSERVATIONAL
Enrollment

964

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

December 31, 2014

Study Completion Date

April 30, 2016

Conditions
Heart Failure (HF)
Trial Locations (1)

08540

GE Healthcare, Princeton

Sponsors

Lead Sponsor

GE Healthcare

Collaborators (1)

H2O Clinical LLC
All Listed Sponsors
collaborator

H2O Clinical LLC

INDUSTRY

collaborator

Quintiles, Inc.

INDUSTRY

lead

GE Healthcare

INDUSTRY

NCT02127307 - Phase 4 Study to Demonstrate Prognostic Usefulness of AdreView™ Scintigraphy for Identifying Subjects With Heart Failure Who Will Experience Death During 60 Months Follow-up. | Biotech Hunter | Biotech Hunter